Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 12/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1351068 | 0.91 | DGAT1 (0.40) | DGAT1JAK2JAK1JAK3ALDH1A1 | |
| SCHEMBL3428480 | 0.85 | DGAT1 (0.36) | DGAT1KLKB1 | |
| SCHEMBL1369630 | 0.85 | JAK3 (0.52) | DGAT1JAK2JAK1JAK3 | |
| SCHEMBL1353887 | 0.85 | JAK2 (0.39) | DGAT1JAK2JAK1JAK3ALDH1A1 | |
| SCHEMBL12372355 | 0.85 | DGAT1 (0.42) | DGAT1ALDH1A1KDM4EMAPK1L3MBTL1 | |
| SCHEMBL1369633 | 0.85 | JAK2 (0.39) | DGAT1JAK2JAK1JAK3KDM4E | |
| SCHEMBL2344724 | 0.84 | DGAT1 (0.35) | DGAT1ALDH1A1KDM4EMAPK1L3MBTL1 | |
| SCHEMBL1696870 | 0.83 | DGAT1 (0.40) | DGAT1JAK2JAK1JAK3 | |
| SCHEMBL2344746 | 0.83 | JAK3 (0.36) | DGAT1JAK3ALDH1A1KDM4E | |
| SCHEMBL12799408 | 0.82 | DGAT1 (0.35) | DGAT1ALDH1A1KDM4EMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250172-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-7902197-B2 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902197-B2 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902197-B2 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2250172-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009106443-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215788-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215788-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215788-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215788-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK2 | DGAT1 4730/4885JAK2 3/4885JAK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.